By Doni Bloomfield
Isis Pharmaceuticals Inc. rose after reporting encouraging results in a small trial aimed at helping babies with a rare spinal disease.
Most of the babies with spinal muscular atrophy who took the treatment, known as ISIS-SMN-RX, have lived longer without permanent ventilation and increased their ability to use their muscles, the Carlsbad, California-based company said in a statement Thursday. Only one of the 19 infants who completed the treatment required permanent ventilation, the company said.
